Literature DB >> 2742603

Glutathione and glutathione S-transferases in a human plasma cell line resistant to melphalan.

V Gupta1, S V Singh, H Ahmad, R D Medh, Y C Awasthi.   

Abstract

We report the development of a melphalan-resistant HS-Sultan human plasma cell line. The melphalan-resistant [MEL(R)] cell line was 16.7-fold more resistant to melphalan in vitro than the parent cell line [MEL(S)]. The wild type and MEL(R) HS-Sultan cell lines formed localized plasmacytomas when injected into nude mice. A dose-response effect of melphalan against the drug-sensitive plasmacytomas was present in vivo. A dose of 10 mg/kg of melphalan, which caused a 90% regression of MEL(S) plasmacytomas, had no effect on the MEL(R) plasmacytomas in vivo. In contrast to previous reports, there was no increase in the levels of glutathione (GSH) in the MEL(S) and MEL(R) plasmacytomas, suggesting that the association of elevated glutathione levels and melphalan resistance may not be common to all drug-resistant lines. In the MEL(R) plasmacytomas, there was a 1.5-fold induction of a pi type glutathione S-transferase (GST) as evidenced by isoelectric focusing (IEF) and Western blotting. This GST isoenzyme was purified and, although immunochemically similar to the pi type isoenzymes induced in other drug-resistant cell lines, was noted to have different functional characteristics. These data suggest that, depending on cell type and the drug studied, functionally different GST isoenzymes may be induced and they could be of importance in the development of drug resistance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2742603     DOI: 10.1016/0006-2952(89)90499-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Glutathione S-transferase pi in an arsenic-resistant Chinese hamster ovary cell line.

Authors:  J F Lo; H F Wang; M F Tam; T C Lee
Journal:  Biochem J       Date:  1992-12-15       Impact factor: 3.857

2.  Proteometabolomics of Melphalan Resistance in Multiple Myeloma.

Authors:  David C Koomen; Joy D Guingab-Cagmat; Paula S Oliveira; Bin Fang; Min Liu; Eric A Welsh; Mark B Meads; Tuan Nguyen; Laurel Meke; Steven A Eschrich; Kenneth H Shain; Timothy J Garrett; John M Koomen
Journal:  Methods Mol Biol       Date:  2019

3.  Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro.

Authors:  Le-Min Lin; Bao-Xin Li; Jian-Bing Xiao; Dan-Hua Lin; Bao-Feng Yang
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

4.  Severe depletion of cellular thiols and glutathione-related enzymes of a carmustine-resistant L1210 strain associates with collateral sensitivity to cyclophosphamide.

Authors:  E Institoris; L Tretter; D Gaál
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.

Authors:  J A Moscow; C A Swanson; K H Cowan
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

6.  Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer cell lines?

Authors:  B G Campling; K Baer; H M Baker; Y M Lam; S P Cole
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

7.  Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.

Authors:  S M Castellino; H S Friedman; G B Elion; E T Ong; S L Marcelli; R Page; D D Bigner; M W Dewhirst
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

8.  Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.

Authors:  K S Lee; H K Kim; H S Moon; Y S Hong; J H Kang; D J Kim; J G Park
Journal:  Korean J Intern Med       Date:  1992-07       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.